36860-49-8Relevant academic research and scientific papers
BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF
-
Paragraph 00297; 00382, (2021/09/26)
The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).
PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF
-
Paragraph 00288; 00593-00596, (2021/09/26)
The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).
Synthetic entry to tricyclic and tetracyclic quinuclidine derivatives by cycloaddition and ring transformation
Hamama, Wafaa S.,Abd El-Magid, Osama M.,Zoorob, Hanafi H.
, p. 93 - 100 (2008/02/11)
The (Z)-2-arylidene-quinuclidines 5-8 were synthesized. Their reaction with aliphatic dibasic functional reagents in both basic and acidic conditions afforded the fused heterocycles 9, 10 and 11. However, the reaction of arylidene derivative 5 with an aromatic dibasic functional reagent gave benzimidazole 13 in lieu of the anticipated tetracyclic system, quinuclidino[3,2-e]benzo[b]-1,4- diazepine 12. Cycloadditions of 5 with different reagents gave the heterocyclic derivatives 17, 19, 22 and 23. Acid-catalyzed cyclization of 5 with excess resorcinol gave 24. Compounds 9a, 19 and 24 showed antibacterial activities.
